Papa John’s International Continues European Expansion and Announces Plans to Enter Madrid, Spain

Papa John’s International today announced the signing of a development agreement to open over 100 restaurants in Madrid and the surrounding area. PJ Espana Pizzerias S.L.., the master franchisee for this agreement, which is a fully owned subsidiary of Drake Enterprises AG, the same owner of the Papa John’s franchisee in Chile, is set to open its first unit during the second quarter of 2016.

Portacool, LLC Expands International Distribution to European Union to Meet Anticipated Summer Demand for Portable Cooling Solutions

Portacool, LLC, the Texas-based global leader in evaporative cooling solutions, is addressing the rise in European demand for its products through a new 3050m2 warehouse facility in Barcelona, opening this month. The trend of hotter summer temperatures across the European continent, coupled with the need for cooler environments for both commercial and leisure pursuits, have seen Portacools business in Europe increase by 12% since 2010, and the company sees significant growth potential as a result of the new warehousing facility in Barcelona.

IPsoft introduces European executives to Amelia during Gartners EMEA Symposium in Barcelona November 9-12

Amelia, the first cognitive virtual agent to interact like a human, is coming to Spain to meet Europes leading CIOs. IPsoft will be sharing a case study of how Amelia is being deployed today at a private event in Barcelonas Hotel Arts on Monday, November 10th. The evening will spark the debate on the hottest issue in business and IT: How artificial intelligence is set to revolutionize business permanently through the introduction of a Digital Workforce.

MSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in Patients with Advanced Bladder Cancer at ESMO 2014

MSD, known as Merck in the United States and Canada, today announced the first presentation of data on the investigational use of pembrolizumab the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer, (also known as bladder cancer). The early findings presented showed a confirmed overall response rate of 24 percent with pembrolizumab as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI, 10.3-43.5) including a complete response rate of 10 percent (3/29). At the time of analysis, response durations ranged from 16+ to 40+ weeks with six of the seven responders continuing on therapy. In the ongoing study, 64 percent (61/95) of patients screened had tumours that were determined to be positive for PD-L1 expression.

Otsuka and The Union Announce Global TB Research & Innovation Award

In recognition of World TB Day 2014, Otsuka SA (Otsuka), in a global partnership with the International Union Against Tuberculosis and Lung Disease (The Union), today issued a call for nominations for its Young Innovator in TB Research Award, aimed at recognizing young scientists who have demonstrated a commitment to advancing innovative thinking in tuberculosis (TB) research.